Dr. Ingrid A Mayer, MD
Claim this profileVanderbilt University/Ingram Cancer Center
Studies Breast Cancer
Studies Cancer
9 reported clinical trials
28 drugs studied
Area of expertise
1Breast Cancer
Stage IV
HER2 negative
ER positive
2Cancer
Stage IV
Stage III
PD-L1 positive
Affiliated Hospitals
Clinical Trials Ingrid A Mayer, MD is currently running
Avelumab Combinations
for Triple Negative Breast Cancer
This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-in of medications that can stimulate the immune system. It is our hope that this induction will improve the response to immunotherapy with avelumab. One treatment, sacituzumab Govitecan, is a monoclonal antibody called sacituzumab linked to a chemotherapy drug called SN-38. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as Tumor-associated calcium signal transducer 2 (TROP2) receptors, and delivers SN-38 to kill them. Another treatment, liposomal doxorubicin, is a form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin, and may enhance factors associated with immune response. The third medication is called binimetinib, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may help activate the immune system. It is not yet known whether giving avelumab in combination with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan will work better in treating patients with triple negative breast cancer.
Recruiting1 award Phase 211 criteria
Sacituzumab Govitecan
for Brain Metastases from Breast Cancer
This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan may shrink the cancer in the brain and/or extend the time until the cancer gets worse.
Recruiting1 award Phase 212 criteria
More about Ingrid A Mayer, MD
Clinical Trial Related3 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Ingrid A Mayer, MD has experience with
- Palbociclib
- Avelumab
- Sacituzumab Govitecan
- Ribociclib
- Liposomal Doxorubicin
- Binimetinib
Breakdown of trials Ingrid A Mayer, MD has run
Breast Cancer
Cancer
Tumors
Endometrial Cancer
Hemangiosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ingrid A Mayer, MD specialize in?
Ingrid A Mayer, MD focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 negative.
Is Ingrid A Mayer, MD currently recruiting for clinical trials?
Yes, Ingrid A Mayer, MD is currently recruiting for 3 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Ingrid A Mayer, MD has studied deeply?
Yes, Ingrid A Mayer, MD has studied treatments such as Palbociclib, Avelumab, Sacituzumab Govitecan.
What is the best way to schedule an appointment with Ingrid A Mayer, MD?
Apply for one of the trials that Ingrid A Mayer, MD is conducting.
What is the office address of Ingrid A Mayer, MD?
The office of Ingrid A Mayer, MD is located at: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee 37232 United States. This is the address for their practice at the Vanderbilt University/Ingram Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.